NASDAQ:JANX

Janux Therapeutics Q2 2025 Earnings Results & Report

Janux Therapeutics logo
$10.31 -0.40 (-3.73%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$10.40 +0.09 (+0.83%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Janux Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$0.55 versus the -$0.48 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Janux Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Janux Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$300 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Janux Therapeutics Q2 2025 Earnings FAQ

Janux Therapeutics (NASDAQ:JANX) reported earnings of -$0.55 per share for Q2 2025, missing the consensus estimate of -$0.48. The report was announced on Thursday, August 7, 2025.

Janux Therapeutics Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Janux Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email.

About Janux Therapeutics

Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors.

Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.

Based in San Diego, California, Janux was founded in 2017. The company is led by co-founder David Campbell, Ph.D., who serves as president and chief executive officer.

View Janux Therapeutics Profile